Christopher Peetz Sells 27,279 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 27,279 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.21, for a total value of $1,206,004.59. Following the sale, the chief executive officer now directly owns 138,641 shares in the company, valued at approximately $6,129,318.61. This trade represents a 16.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Christopher Peetz also recently made the following trade(s):

• On Monday, February 3rd, Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44.
• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98.

Mirum Pharmaceuticals Stock Performance

Shares of Mirum Pharmaceuticals stock opened at $47.13 on Thursday. The stock has a market cap of $2.31 billion, a price-to-earnings ratio of -23.33 and a beta of 1.04. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company’s fifty day moving average is $47.65 and its 200 day moving average is $43.62. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. Sell-side analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Summit Investment Advisors Inc. increased its position in shares of Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company’s stock worth $172,000 after buying an additional 312 shares during the period. Jones Financial Companies Lllp grew its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after acquiring an additional 357 shares during the period. Schonfeld Strategic Advisors LLC raised its position in shares of Mirum Pharmaceuticals by 2.9% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 17,200 shares of the company’s stock worth $711,000 after acquiring an additional 487 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Mirum Pharmaceuticals in the 4th quarter valued at about $35,000. Finally, Legato Capital Management LLC boosted its position in shares of Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after purchasing an additional 977 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright boosted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $58.20.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.